AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Summary

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Solid Tumor Cancer
• Locally Advanced
• Metastatic Solid Tumors
• Lung Cancers
• Epithelial Tumor
• Biliary Tract Cancer (BTC)
• Urothelial Cancer
• Nasopharyngeal Cancers

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Avenzo Therapeutics, Inc.

Last updated on ClinicalTrials.gov

September 4, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites